Replimune (REPL) Preferred Stock Liabilities (2018)

Replimune's (REPL) quarterly Preferred Stock Liabilities came in at $86.4 million in Q2 2018, little changed quarter-over-quarter from $86.4 million in Q1 2018.

Replimune (REPL) Preferred Stock Liabilities (2018) Analysis & Trends

Replimune has disclosed Preferred Stock Liabilities across 1 years of filings, most recently posting $86.4 million for Q2 2018.

  • Preferred Stock Liabilities for Q2 2018 came in at $86.4 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2018 was $86.4 million (changed N/A YoY), and the FY2018 annual result was $86.4 million, up 173.22% from the prior year.
  • Preferred Stock Liabilities came in at $86.4 million for Q2 2018 at Replimune, roughly flat from $86.4 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $86.4 million in Q1 2018 to a low of $86.4 million in Q1 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - -
7 Psyence Biomedical 227.32 Bn 227.31 Bn - -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn -
9 Abivax 91.71 Bn 91.71 Bn - -
10 Replimune 780.01 Mn 510.88 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2018 86.36 Mn
Mar 31, 2018 86.36 Mn